Close Menu

Life at Lilly

It's tough times at Eli Lilly with patents ending, failed drugs, among other problems, reports the New York Times. But CEO John Lechleiter says that Lilly doesn't need to turn to mergers or acquisitions to jump-start the company; he says they can rely on in-house research and cost-cutting. "At a time when others say Lilly has to do a deal or Lilly has to go outside itself to solve its problems, we're resolutely focused on what we have to do inside the company," Lechleiter says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.